Physician profile
Michael Chang
NPI 1427318336
$644.48
in general payments reported to CMS, 2019-2025
12 companies · $153 in 2025
The $153 reported for 2025 was more than what 76% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $436 · 2024: $54.80 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $644.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $128.46 | 2023 | |
| Roche Diagnostics Corporation | $87.46 | 2023 | |
| Stryker Corporation | $80.96 | 2023 | Cascadia Interbody System, Everest Spinal System, Ravine Lateral Access System |
| Astrazeneca Pharmaceuticals Lp | $76.68 | 2023 | Enhertu |
| Celgene Corporation | $50.00 | 2023 | Reblozyl |
| Lilly USA, LLC | $48.72 | 2024-2025 | Omvoh |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.36 | 2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $44.30 | 2025 | Gattex, Entyvio |
| Madrigal Pharmaceuticals | $25.81 | 2024 | Resmetirom |
| Exact Sciences Corporation | $22.84 | 2025 | The Cologuard Plus Collection Kit |
| Janssen Biotech, INC. | $18.16 | 2025 | Tremfya |
| Cordis US Corp. | $12.73 | 2023 | Saber |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.